Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial - Walgaard, C; Jacobs, B C; Lingsma, H F; Dutch GBS Study Group (Lancet Neurol, 2021)